U.S. authorities instruct manufacturers to include warning labels regarding the rare risk of eye disorders associated with GLP-1 formulations
The U.S. Food and Drug Administration (FDA) on Wednesday ordered manufacturers of GLP-1 receptor agonists such as Manjaro and Ugobi, which are used to treat diabetes and obesity, to add warnings about rare eye diseases that can cause sudden blindness.
Read more











